Sugi Predict

Sugi Predict / Compounds / SCHEMBL10180239

SCHEMBL10180239

SCHEMBL10180239

CC(C)(C)OC(=O)NCc1ccc(/C(N)=N/O)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.51
▸ HDAC1 Q13547 4/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ HPN P05981 1/20 0.45
▸ EPHX2 P34913 2/20 0.45
▸ NR1H4 Q96RI1 1/20 0.45
▸ HDAC6 Q9UBN7 2/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ FPR3 P25089 1/20 0.42
▸ FPR2 P25090 1/20 0.42
▸ GRM2 Q14416 1/20 0.42
▸ HDAC2 Q92769 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17684726 1.00 NAMPT (0.51) NAMPTHDAC1L3MBTL1CA1CA2
SCHEMBL17684727 1.00 NAMPT (0.51) NAMPTHDAC1L3MBTL1CA1CA2
SCHEMBL18986655 0.86 HDAC1 (0.52) NAMPTHDAC1CA1CA2HDAC2
SCHEMBL13979656 0.86 NAMPT (0.49) NAMPTHDAC1L3MBTL1CA1CA2
SCHEMBL18986654 0.86 HDAC1 (0.52) NAMPTHDAC1CA1CA2HDAC2
SCHEMBL8220824 0.85 EPHX2 (0.60) NAMPTHDAC1L3MBTL1CA1CA2
SCHEMBL24832467 0.85 HDAC1 (0.48) NAMPTHDAC1L3MBTL1CA1CA2
SCHEMBL3455893 0.84 GLS (0.46) NAMPTHDAC1NR1H4HDAC6HDAC10
SCHEMBL3455892 0.84 GLS (0.46) NAMPTHDAC1NR1H4HDAC6HDAC10
SCHEMBL18300399 0.84 NAMPT (0.47) NAMPTHDAC1L3MBTL1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486278-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-12-02 — — US disclosed
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2024-03-21 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
EP-3328843-B1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2022-10-26 — — EP disclosed
CN-107922362-B 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社钟根堂 2021-06-15 — — CN disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 — — EP disclosed
EP-2751141-B1 STABLE PEPTIDE-BASED PACE4 INHIBITORS SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) 2018-03-21 — — EP disclosed
US-20140206622-A1 STABLE PEPTIDE-BASED PACE4 INHIBITORS SOCPRA Sciences Sante et Humaines S.E.C. (CA) 2014-07-24 — — US disclosed
WO-2013138666-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-09-19 — — WO disclosed
WO-2013138665-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-09-19 — — WO disclosed
WO-2013029182-A1 STABLE PEPTIDE-BASED FURIN INHIBITORS SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) 2013-03-07 — — WO disclosed
WO-2013029180-A1 STABLE PEPTIDE-BASED PACE4 INHIBITORS SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) 2013-03-07 — — WO disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 — — US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 — — US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 — — US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 — — US disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NAMPT 1282/4885HDAC1 1760/4885L3MBTL1 2417/4885
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 NAMPT 3687/4885HDAC1 38/4885L3MBTL1 3609/4885
US-12486278-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NAMPT 1282/4885HDAC1 1760/4885L3MBTL1 2417/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 NAMPT 1282/4885HDAC1 1760/4885L3MBTL1 2417/4885
US-20140206622-A1 STABLE PEPTIDE-BASED PACE4 INHIBITORS FURIN, DNPEP, PRAP1 NAMPT 509/4885HDAC1 1946/4885L3MBTL1 1944/4885
US-20240092788-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 NAMPT 1282/4885HDAC1 1760/4885L3MBTL1 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.